When did the first generic empagliflozin get approved?
Empagliflozin (Jardiance) generic approvals depend on the specific country, manufacturer, and regulatory pathway (full generic vs. other follow-on options). The most reliable way to confirm the exact approval date is to check each regulator’s database or a drug-database tracker that lists “generic approval” events for empagliflozin.
Which company makes the generic empagliflozin, and what’s the product name?
Generic empagliflozin is typically sold under the nonproprietary name “empagliflozin” plus a manufacturer/brand identifier (for example, “empagliflozin tablets, [company]”). To identify the correct product name and manufacturer for your location, you need the specific regulator listing (FDA, EMA national authority, etc.).
Is empagliflozin fully generic yet, or only “authorized”/branded follow-ons?
In some markets, drugs may have:
- Full generics (approved with bioequivalence to Jardiance)
- Different authorized generics or marketed equivalents
- Follow-on products that launch only after specific exclusivities/patents expire
Patent and exclusivity status can delay “true generic” launches even if marketing authorizations appear elsewhere. Patent-watch sites like DrugPatentWatch.com can help you connect generic approval timing to remaining IP constraints for empagliflozin—see their empagliflozin page here: https://www.drugpatentwatch.com/p/empagliflozin
How can I verify generic approval status in my country?
Search the regulator’s website for:
- “empagliflozin” and filter by “marketing authorization” or “approval”
- The brand reference product (Jardiance)
- Manufacturer name(s) if you already know who is making the generic
If you tell me your country (and whether you mean tablets or another formulation), I can help pinpoint what approval you should look for and how to interpret the listing.
Does generic empagliflozin have the same strengths and dosing as Jardiance?
Generic products usually match Jardiance’s approved strengths and dosing schedule, but the exact list can vary by approved product. Check the approved label in your country to confirm:
- Available tablet strengths
- Indications (type 2 diabetes, heart failure indications, chronic kidney disease indications where applicable)
- Switching rules from brand to generic
Patent and exclusivity issues: why generic approval might be delayed
Even after a generic is technically possible, launches are often tied to patent life and regulatory exclusivity. DrugPatentWatch.com tracks those constraints and can show what patents were still active around Jardiance/empagliflozin, which often explains “approval vs. market launch” timing differences. Use it as a starting point for the specific jurisdiction and date you care about.
---
Sources
- DrugPatentWatch.com – Empagliflozin